Mouse Lipocalin-13 Alexa Fluor® 647-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: Lipocalin-13

LCN-13 (Lipocalin 13; also Odorant-binding protein 2a) is a secreted, 26-28 kDa member of the LCN family, calycin superfamily of molecules. Its name is derived from Greek, and denotes the fact that lipocalins are known to be "fat-wrapping", or fat binding proteins that interact with small lipophilic molecules within a central cavity. LCN-13 is expressed by hepatocytes and smooth muscle cells. It is known to have antidiabetogenic effects, including the suppression of hepatic glucose production, the uptake of circulating glucose by adipocytes, and the induction of fatty acid oxidation by liver, possibly by stimulating CPT1 alpha production. Mouse LCN‑13 is synthesized as a 176 amino acid (aa) precursor that contains a 19 aa signal sequence and a 157 aa mature region. Although no splice forms have been reported for LCN-13 to date, a smaller, presumably proteolytically processed 23-26 kDa isoform has been noted on SDS-PAGE. Mature mouse LCN-13 shares 69% and 39% aa sequence identity with rat LCN-13 and human odorant-binding protein 2b, respectively.

Product Datasheets

Related Research Areas

• Diabetes
• Obesity